演題詳細

ポスター / Poster

ポスター 3 (Poster 3) :鉄キレート療法 (Iron Chelate Therapy)

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
藤島 眞澄 (Masumi Fujishima):1
1:秋田大学医学部 血液・腎臓・膠原病内科学
 
前へ戻る

Use experience of deferasirox in single institute

演題番号 : PS-1-20

杉元 啓二 (Kei-Ji Sugimoto):1、島田 麻美 (Asami Shimada):1,2、若林 睦 (Mutsumi Wakabayashi):1、今井 英則 (Hidenori Imai):1、関口 康宣 (Yasunobu Sekiguchi):1、澤田 朝寛 (Tomohiro Sawada):3、中村 紀子 (Noriko Nakamura):3、小松 則夫 (Norio Komatsu):2、野口 雅章 (Masaaki Noguchi):1

1:Department of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan、2:Department of Hematology, Juntendo University, Tokyo, Japan、3:Division of Clinical Laboratory, Juntendo University Urayasu Hospital, Chiba, Japan

 

[Introduction] Deferasirox (DFX) is an oral iron chelator preparation that has been found to have an iron-removing effect, but in recent years it has been reported that when DEF administration is started after the iron values in the body have become high, it has been necessary to start treatment at high doses, and there have been cases in which it was impossible to continue because of adverse effects, etc. [Methods] We utilized the blood transfusion management system (BTDX2) used in our hospital to determine total blood transfusion volume. We determined the iron chelator therapy starting time by arranging so that total transfusion blood volume would be stated on drug requisition lists by means of an option setting. [Results] DEF was administered to 11 patients between January and December 2012. The median interval between the time of the diagnosis and start of transfusion was 2 months, and the median interval between the start of transfusion and the start of DFX therapy was 3 months. The median total blood transfusion volume at the time DEF administration was started was 20 units, and the median dose of DEF at the start of administration was 250 mg. The median serum ferritin (FER) value 12 months after the start of treatment was 477.7 ng. [Discussion] Total blood transfusion management became possible by simple customizing of the blood transfusion system, thereby making it possible to perform iron chelator therapy at the appropriate time. That made it possible to start DEF therapy early, and improvements in transfusion frequency and serum FER values were observed.

前へ戻る